Stay updated on Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial
Sign up to get notified when there's something new on the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page.

Latest updates to the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal regarding the study of SB-913 for Mucopolysaccharidosis II, including detailed descriptions of the study's purpose, objectives, and inclusion/exclusion criteria. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference20%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ascending Dose Study of ZFN Therapeutic SB-913 in MPS II Clinical Trial page.